Previous 10 | Next 10 |
DUBLIN , Nov. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, Dec. 3, 2019 at 8:00 a.m. ET ( 1:00 p...
Alkermes (NASDAQ: ALKS ) completes acquisition of Rodin Therapeutics, a privately held biopharmaceutical company. More news on: Alkermes plc, Healthcare stocks news, Read more ...
DUBLIN , Nov. 25, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a privately held biopharmaceutical company. This transaction builds on Alkermes' experience in cen...
The following slide deck was published by Alkermes plc in conjunction with this Read more ...
DUBLIN , Nov. 19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the...
Alkermes plc (NASDAQ: ALKS ) has agreed to acquire privately held Rodin Therapeutics , a developer of small molecule therapies to treat synaptopathies, expanding its development activities in neurodegenerative disorders. More news on: Alkermes plc, Healthcare stocks news, Merger & a...
DUBLIN and BOSTON , Nov. 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused on dev...
In a statement released yesterday, the National MS Society expressed disappointment with the wholesale acquisition cost (WAC) of Vumerity (diroximel fumarate), approved by FDA on October 30 for relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcar...
DUBLIN , Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of VUMERITY™ (diroximel fumarate), a novel oral fumarate ...
DUBLIN , Nov. 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for Immunotherapy of Cancer's (SITC) 34 th Annual Meeting in National Harbor, MD. ALKS 4230 is an...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...